{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:41:31Z","timestamp":1776505291810,"version":"3.51.2"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/ftd.0000000000000013","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T10:02:24Z","timestamp":1387188144000},"page":"410-412","source":"Crossref","is-referenced-by-count":12,"title":["Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia"],"prefix":"10.1097","volume":"36","author":[{"given":"Silvia","family":"De Francia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ariaudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Piccione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Simiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210129","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":". Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-20-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as paradigm of targeted therapies.","volume":"91","author":"Druker","year":"2004","journal-title":"Adv Cancer Res"},{"key":"R3-20-20210129","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":". Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"R4-20-20210129","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":". Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-20-20210129","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":". Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"R6-20-20210129","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib.","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R7-20-20210129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":". Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20-20210129","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","article-title":". Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL() leukemic cells to the abl inhibitor STI571.","volume":"92","author":"Gambacorti-Passerini","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R9-20-20210129","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.beha.2009.09.007","article-title":"Pharmacologic monitoring and determinants of intracytoplasmic drug levels.","volume":"22","author":"Mahon","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"R10-20-20210129","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":". Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"R11-20-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","article-title":". Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders.","volume":"65","author":"Singh","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-20-20210129","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":". Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"R13-20-20210129","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":". Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study.","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"R14-20-20210129","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/chrsci\/49.10.753","article-title":". A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.","volume":"49","author":"Pirro","year":"2011","journal-title":"J Chromatogr Sci"},{"key":"R15-20-20210129","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","article-title":". Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LCMS-MS.","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin Chim Acta"},{"key":"R16-20-20210129","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.leukres.2009.11.009","article-title":". Simultaneous determination of nilotinib, imatinib and its main metabolite (CGO-74588) in human plasma by ultra-violet high performance liquid chromatography.","volume":"34","author":"Davies","year":"2010","journal-title":"Leuk Res"},{"key":"R17-20-20210129","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","article-title":". New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.","volume":"877","author":"De Francia","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R18-20-20210129","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/bmc.1247","article-title":". Development and validation of a sensitive assay for the quantification of imatinib using LCLC-MSMS in human whole blood and cell culture.","volume":"23","author":"Klawitter","year":"2009","journal-title":"Biomed Chromatogr"},{"key":"R19-20-20210129","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.cca.2010.08.014","article-title":". Flow injection analysis vs. ultra high-performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma.","volume":"411","author":"Micova","year":"2010","journal-title":"Clin Chim Acta"},{"key":"R20-20-20210129","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","article-title":". Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.","volume":"27","author":"Titier","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R21-20-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-009-0008-0","article-title":". Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.","volume":"97","author":"Holdhoff","year":"2010","journal-title":"J Neurooncol"},{"key":"R22-20-20210129","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1248\/bpb.34.114","article-title":". Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia.","volume":"34","author":"Nambu","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"R23-20-20210129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000336244","article-title":". Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients.","volume":"127","author":"Zhong","year":"2012","journal-title":"Acta Haematol"},{"key":"R24-20-20210129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpba.2011.10.003","article-title":". HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).","volume":"59","author":"DAvolio","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"R25-20-20210129","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1128\/AAC.01236-10","article-title":". Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.","volume":"55","author":"Simiele","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20-20210129","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jac\/dks484","article-title":". Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.","volume":"68","author":"DAvolio","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R27-20-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jpba.2010.10.011","article-title":". A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.","volume":"54","author":"DAvolio","year":"2011","journal-title":"J Pharm Biomed Anal"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:27:58Z","timestamp":1620952078000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201406000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000013","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}